Alnylam (ALNY) PT Raised to $138 at BMO Capital Following Givlaari Early Approval With Favorable Label
Tweet Send to a Friend
BMO Capital analyst Do Kim raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $138.00 (from $128.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
